CRN priorities for CFSAN
This article was originally published in The Tan Sheet
The Council for Responsible Nutrition asks FDA to prioritize providing guidance and conducting stakeholder meetings with industry on implementing the dietary supplement good manufacturing practices final rule, CRN says in comments submitted Aug. 29. Other CRN recommendations include FDA adding reviewers to expedite the Center for Food Safety and Applied Nutrition's evaluation of adverse event reports, which supplement and OTC firms will be required to submit beginning in December under the AER law Congress enacted in 2006, and to amend the MedWatch form to include space to indicate whether consumers say they will allow their physicians to speak with firms' medical representatives (1"The Tan Sheet" Aug. 20, 2007, p. 13)...
You may also be interested in...
FDA's guidance on adverse event reporting for OTC drugs and dietary supplements should assure that firms operating outside the country can use U.S. addresses on their product labels but receive AER-related communication in their home countries, the American Herbal Products Association recommends
Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.
A medicines manufacturing “road map” set out by Australia’s government has the backing of the local off-patent industry.